OVID

+ Watchlist + Portfolio

Ovid Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.74
52-Week Range: $0.94 – $3.11
Market Cap: $545.86M
P/E (TTM): —
EPS (TTM): -0.21
Dividend Yield: —

Advanced Metrics

Price/Book: 2.46
PEG Ratio: —
Return on Equity: -25.96%
Return on Assets: -23.46%
Gross Margin: 100.00%
Operating Margin: -2100.68%
Profit Margin: 0.00%
Current Ratio: 12.39
Debt/Equity: 0.06
Total Debt: $12.71M
Free Cash Flow: $-33.12M
Revenue Growth: -88.30%
Earnings Growth: —
Enterprise Value: $430.61M

OVID Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.50M	$392.00K	$566.00K	$7.25M
Research & Development	$24.62M	$28.59M	$36.77M	$25.58M
Selling, General & Admin	$32.43M	$31.09M	$25.68M	$24.11M
Operating Expenses	$57.05M	$59.67M	$62.45M	$49.69M
Operating Income	-$55.55M	-$59.28M	-$61.88M	-$42.44M
EBITDA	-$54.17M	-$58.71M	-$61.27M	-$42.17M
Pretax Income	-$54.17M	-$52.34M	-$26.43M	-$17.41M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$54.17M	-$52.34M	-$26.43M	-$17.41M
Diluted EPS	-0.77	-0.73	-0.37	-0.23
Diluted Shares	70.42M	70.58M	70.91M	73.74M

OVID Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$44.87M	$27.04M	$26.30M	$13.15M
Current Assets	$131.38M	$109.60M	$55.94M	$74.37M
Total Assets	$155.27M	$144.03M	$92.17M	$150.93M
Current Liabilities	$6.99M	$11.47M	$10.52M	$8.29M
Total Debt	$16.54M	$16.00M	$14.76M	$13.42M
Total Liabilities	$22.99M	$56.23M	$23.94M	$20.27M
Retained Earnings	-$225.53M	-$277.87M	-$304.30M	-$321.71M
Shareholders' Equity	$132.27M	$87.80M	$68.23M	$130.66M
Working Capital	$124.39M	$98.13M	$45.42M	$66.08M

OVID Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$55.23M	-$45.78M	-$55.96M	-$38.33M
Capital Expenditure	-$1.42M	-$137.00K	-$161.00K	—
Free Cash Flow	-$56.65M	-$45.92M	-$56.12M	-$38.33M
Depreciation & Amortisation	$1.38M	$568.00K	$613.00K	$273.00K
Stock-Based Compensation	$6.56M	$7.29M	$6.28M	$4.81M
Investing Cash Flow	-$87.88M	-$2.58M	$54.59M	-$49.85M
Financing Cash Flow	$180.66K	$30.54M	$622.00K	$75.21M
Net Change in Cash	-$142.93M	-$17.83M	-$740.00K	-$12.98M

OVID Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$130.00K	$6.27M	$132.00K	$718.00K	$0.00
Research & Development	$6.66M	$6.46M	$5.87M	$6.59M	$11.18M
Selling, General & Admin	$6.02M	$4.88M	$6.79M	$6.42M	$6.67M
Operating Expenses	$12.68M	$11.35M	$12.65M	$13.01M	$17.85M
Operating Income	-$12.55M	-$5.07M	-$12.52M	-$12.29M	-$17.85M
EBITDA	-$12.41M	-$4.97M	-$12.51M	-$12.28M	-$17.81M
Pretax Income	-$10.23M	-$4.68M	-$12.16M	$9.66M	-$16.99M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$10.23M	-$4.68M	-$12.16M	$9.66M	-$16.99M
Diluted EPS	-0.14	-0.06	-0.17	0.06	-0.12
Diluted Shares	71.05M	71.11M	71.12M	81.67M	136.17M

OVID Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$21.14M	$28.41M	$20.61M	$13.15M	$94.06M
Current Assets	$45.92M	$42.09M	$28.82M	$74.37M	$160.15M
Total Assets	$81.65M	$77.43M	$63.85M	$150.93M	$225.63M
Current Liabilities	$9.31M	$8.92M	$6.80M	$8.29M	$15.75M
Total Debt	$14.43M	$14.10M	$13.76M	$13.42M	$13.07M
Total Liabilities	$22.38M	$21.64M	$19.15M	$20.27M	$27.36M
Retained Earnings	-$314.53M	-$319.22M	-$331.38M	-$321.71M	-$338.70M
Shareholders' Equity	$59.28M	$55.79M	$44.70M	$130.66M	$198.27M
Working Capital	$36.61M	$33.16M	$22.03M	$66.08M	$144.40M

OVID Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$10.28M	-$4.77M	-$12.87M	-$10.41M	-$13.90M
Free Cash Flow	-$10.28M	-$4.77M	-$12.87M	-$10.41M	-$13.90M
Depreciation & Amortisation	$141.00K	$99.00K	$16.00K	$17.00K	$35.00K
Stock-Based Compensation	$1.28M	$1.22M	$1.11M	$1.20M	$1.05M
Investing Cash Flow	$5.10M	$12.05M	$5.05M	-$72.06M	$5.95M
Financing Cash Flow	$13.00K	$0.00	$15.00K	$75.18M	$88.98M
Net Change in Cash	-$5.17M	$7.28M	-$7.80M	-$7.29M	$81.03M

Market Snapshot

About

Ovid Therapeutics Inc. is a biopharmaceutical company developing medications for rare neurological disorders. The company focuses on therapies for conditions such as Angelman syndrome, epilepsies, and other rare neurological diseases with significant unmet medical needs. Ovid Therapeutics advances both internally developed programs and in-licensed candidates through clinical development.